Rasha Dabbour
Research Subjects
Research Interests
Rasha Dabbour has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad M. Al-Bashaireh
Faculty of Nursing, Philadelphia University, Amman 11118, Jordan
1 shared publication - Ayman Jaber Hammoudeh
Department of Cardiology, Istishari Hospital, Amman 11184, Jordan
1 shared publication - Aysam I. Hweidi1 shared publication
- Husam A. Alsalamat
Al‐Balqa Applied University Al Salt Jordan
1 shared publication - Lourance Al Hadid
Faculty of Nursing, Al-Balqa Applied University, Salt, Jordan
1 shared publication - Omar Qaladi
Department of Community and Psychiatric Mental Health Nursing, College of Nursing, King Saud University, Riyadh 12372, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 12 January 2024
- Published by MDPI AG in Preprints.org
Analysis of a Cohort of Patients with Atrial Fibrillation on Warfarin: The Jordan Atrial Fibrillation Study (JoFib)
(1) Background: Most patients with atrial fibrillation, on warfarin therapy, are at higher risk of morbidity and mortality. However, data targeting patients with atrial fibrillation, who take warfarin therapy, are limited in Jordan. This study aimed to provide in-depth analysis of a cohort of patients with atrial fibrillation on warfarin regarding patients’ characteristics, atrial fibrillation related symptoms, interventions, comorbidities, and 12-months outcomes. (2) Methods: The study enrolled 645 patients with atrial fibrillation, on warfarin, from 28 health settings across Jordan. Standardized clinical data form was utilized to collect data upon enrollment, at one, six, and 12 months post initial assessment. Descriptive statistics were used for the description of variables. (3) Results: The most commonly reported symptoms were palpitation (41.4%) shortness of breath (39.1%) and fatigue (26.2%). The prevalent comorbidities associated with atrial fibrillation were congestive heart failure (22.5%), valvular heart diseases (16.6%), and cerebral vascular accident (16.3%). The embolic (32.4%) and thrombotic cerebral vascular accident (16.2%) were the most common type. Major bleeding associated with hospitalization was the most frequent type of bleeding (10 out of 24). (4) Conclusions: Jordanians, using anticoagulation, need to be constantly monitored in terms of their characteristics, symptoms, and any potential complications, to ensure its optimal therapeutic dose and prevent any potential health complications.
- 12 January 2024
- Published by MDPI AG in Preprints.org
Open AccessAnalysis of a Cohort of Patients with Atrial Fibrillation on Warfarin: The Jordan Atrial Fibrillation Study (JoFib)
(1) Background: Most patients with atrial fibrillation, on warfarin therapy, are at higher risk of morbidity and mortality. However, data targeting patients with atrial fibrillation, who take warfarin therapy, are limited in Jordan. This study aimed to provide in-depth analysis of a cohort of patients with atrial fibrillation on warfarin regarding patients’ characteristics, atrial fibrillation related symptoms, interventions, comorbidities, and 12-months outcomes. (2) Methods: The study enrolled 645 patients with atrial fibrillation, on warfarin, from 28 health settings across Jordan. Standardized clinical data form was utilized to collect data upon enrollment, at one, six, and 12 months post initial assessment. Descriptive statistics were used for the description of variables. (3) Results: The most commonly reported symptoms were palpitation (41.4%) shortness of breath (39.1%) and fatigue (26.2%). The prevalent comorbidities associated with atrial fibrillation were congestive heart failure (22.5%), valvular heart diseases (16.6%), and cerebral vascular accident (16.3%). The embolic (32.4%) and thrombotic cerebral vascular accident (16.2%) were the most common type. Major bleeding associated with hospitalization was the most frequent type of bleeding (10 out of 24). (4) Conclusions: Jordanians, using anticoagulation, need to be constantly monitored in terms of their characteristics, symptoms, and any potential complications, to ensure its optimal therapeutic dose and prevent any potential health complications.